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(Spp1) in microglia-activating fractions. Both osteopontin and lac-
tadherin are avb3/avb5 integrin ligands able to interact with
receptors present on microglia and macrophages and thus could
be involved in pro-invasive polarization of microglia/
macrophages. Moreover, both Spp1 and Mfge8 are overexpressed
in glioma cells, but not in non-transformed astrocytes. C6 glioma
cells stably expressing shRNA specific to lactadherin (shMfge8),
osteopontin (shSpp1) and negative shRNA (shNeg) were
implanted into striatum of Wistar rats. There was no difference
in proliferation and viability of C6 glioma cells, cells stably
expressing shRNA specific to lactadherin, ostopontin and nega-
tive shRNA in vitro, that demonstrates the negligible effect of
autocrine production of both protein on tumor cell growth.
Knockdown of Spp1 and Mfge8 resulted in significant reduction
of tumor volume in rat model of glioma. Immunochemical anal-
ysis of brain sections revealed similar numbers of infiltrating
microglia/macrophages (Iba1 staining), but the reduced number
of ameboid, arginase 1 expressing cells in Mfge8 – depleted tumor.
Treatment of endothelial cells with rhMFGE8 revealed significant
effect of that protein on angiogenesis in vitro, however
lactadherin-depleted tumors do not exhibit reduced blood vessel
density in rat glioma model. FACS analysis showed that silencing
of Spp1 does not affect total number of CD11b-positive cells, but
strongly modulates microenvironment by leading to significant
changes in percentage of Tc and Treg cells infiltrating tumor-
bearing hemisphere. Our results suggest that glioma-derived
integrin ligands are important factor in polarization of glioma
infiltrating microglia/macrophages into the pro-invasive pheno-
type and its targeting could be a new therapeutic strategy.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.081
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It’s well documented that cytokines in patients with breast
cancer are indicators of survival, assessing the risk of recurrence
and mortality. However, the obtained data about serum levels of
cytokines are contradictory. The problem of participation of
cytokines in the growth and spread of tumors requires further
study.
The purpose was the determination of serum level of cytokine
in experimental model of breast cancer in Wistar rat. Material
and methods: Breast cancer was induced by intramammalirian
injection of N-methyl-N-nitrosourea. Some of the rats were sub-
jected to only surgery or only polychemotherapy (cyclophos-
phamide, methotrexate, 5-fluorouracil).Serum levels of
cytokines: Bio-Plex Pro Rat Cytokines 24-Plex Assay (Bio-Rad,
USA) were used.
Results: It was found that the serum levels of IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-12, IL-13, IL-17A, IFN -c, MIP-1a, MIP-3a, RANTES,
TNF-a in rats with experimental breast cancer were significantly
higher compared with intact rats. We obtained that pro-
inflammatory cytokines are associated with progression of breast
cancer in rats. The serum levels of IL-1a, IL-2, IL-4, IL-12, IL-18,
G-CSF, GM-CSF, GRO/KC, IFN-c, MIP-1a, RANTES in rats after
surgical treatment were significantly higher compared to those
in rats without surgical treatment. It was also observed that in
rats after surgical treatment,the serum levels of IL-1a, IL-2, IL-4,
IL-12, IL-18, G-CSF, GM-CSF, GRO/KC, IFN-c, MIP-1a, RANTES were
decreased. We suppose that these data may indicate that tumor
cells can also produce cytokines. Moreover, we obtained that in
intact rats, serum levels of IL-1a, IL-18, EPO, G-CSF, GRO/KC,
MIP-1a were higher compared to those in rats with breast
cancer treated with surgery. However, the serum levels of IL-6
and IL-1b (markers of pro- inflammation and tumor metastasis)
were higher in surgically treated rats compared to those in intact
rats. It has been proved that the removal of primary tumors
(without regional lymph node removal and subsequent poly-
chemotherapy) can lead to accelerated growth of metastases. It
was found that the polychemotherapy resulted in a significant
decrease in the serum levels of IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-10, IL-12, IL-13, IL-17A, IL-18. Polychemotherapy also leads
to suppression in serum levels RANTES, VEGF, MCP-1. We found
that the serum levels of IL-2, IL-5, IL-7, IL-13, IL-17A, IL-18,
G-CSF were significantly higher in rats after combination of
surgery and polychemotherapy.
Conclusion: The serum level of cytokines in rats with experi-
mental breast cancer depends on the type of treatment.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.082
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Colon adenocarcinoma is one of the most wide spreading
malignant tumors in the world, mortality of which remains high.
Estimation of cancer on late stages, absence of prognostic and
predictive factors, poor understanding of progression mechanism
may lead to elevation of mortality.
The aim of investigation was to identify morphologic prognos-
tic factors and their combination for colon adenocarcinoma.
For this purpose 776 patients with colon adenocarcinoma with
the median age 57.6 years were selected. Receptors for chemokine
(CCR10, CXCR4), stem cell marker (ALDH1), ki-67, MSH2, MSH6,
MLH1, PMS2 were investigated by immunohistochemistry (IHC).
Results of IHC were compared with clinical data. Analysis of 217
colon adenocarcinomas by Ki-67 showed that 86% of cases had
high proliferative level (Ki-67>30%), among them 39% of cases
had very high level of Ki-67 (>70%). We also analyzed proliferation
of stem cells using double IHC stain for ALDH1 and Ki-67. It was
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shown that ALDH1 positive cells had significantly lower Ki-67
positivity than ALDH1 negative cells (p<0,001). ALDH1 positive
cells never have proliferative level more than 10%.
Nowadays development of metastases often relates to interac-
tion between chemokines and their receptors. In our study we
analyze two receptors: CCR10 and CXCR4 as most known in
literature data.
Investigation of CCR10 and CXCR4 shows, that 77% of colon
cancers have expression of CXCR4 and no one – CCR10. It was
found that low level of proliferation (Ki-67<30%) and expression
of CXCR4 were more often revealed in disseminated cancer (IV
stage) than in localized (II stage), p=0.002. The 5-year relapse- free
survival rate in patients with Ki- 67>70% and CXCR4<30% was
75% and 25%, respectively, with median survival time of 16.5
months. Vice versa cases with CXCR4>70% and Ki-67<30% hadthe
5- year relapse-free survival rates of 32% and in 68%, respectively,
with the median survival time of 7 month. IHC study of MSH2,
MSH6, PMS2, MLH1 shows that at least lack of one marker always
accompanies by microsatellite instability. Mutations of these
markers were accompanied by lack of expression in 100% of
cases. Thus, according to modern classification of colon cancer
grade, we divided 45 cases into low and high grades using only
histological criteria and additionally – IHC investigation of
MSH2, MSH6, PMS2, MLH1. It was shown that in 9% of cases
IHC of these markers prevent incorrect evaluation of cancer
grade. Conclusion: immunohistochemical investigation of CXCR4,
Ki-67, MSH2, MSH6, PMS2, MLH1 may be additional useful prog-
nostic factors for patients with colon adenocarcinoma.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.083
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Melanoma is defined as heterogeneous and complex neoplas-
tic system. Melanoma tumor microenvironment composes of
different cell types including tumor-associated lymphocytes,
macrophages, fibroblasts, etc. These cells may intensify tumor
growth and progression by releasing various active substances.
MicroRNAs are a class of posttranscriptional regulators, which
play an essential role in proliferation, adhesion, motility and
migration of cancer cells. Several studies showed that microRNAs
produced by tumor microenvironment cells could act as
paracrine modulators for modification of cancer cells biological
behavior. For identification of melanoma microenvironment
microRNA profile we performedmicroarray analysis of melanoma
samples (n = 10) obtained from Krasnoyarsk Territory Oncological
Center and macrodissected to separate tumor complexes and
tumor microenvironment.
RNA was extracted from tissue samples by MirVana kit
(Ambion, Life Technologies, Canada) in accordance to manufac-
turer recommendations. The microRNA concentration was
measured by Qubit 2.0 Fluorimeter (Life technologies Holdings
Pte Ltd., USA). miRNA expression profiles were processed by the
Affimetrix microarray system (Affymetrix, Santa Clara, CA,
USA). Expression changes between melanoma and nevi samples
were identified using P-value of 0,05. 2.0-fold difference in either
direction was a minimal fold change expression required. A hier-
archical clustering analysis for differentially expressed miRNAs
was carried out by Transcriptome Analysis Console 2.0.
24 microRNAs were identified with altered expression levels in
melanoma cells as compared to tumor microenvironment cells
including hsa-miR-106a-5p, hsa-miR-3178, hsa-miR-223-3p,
hsa-miR-17-5p, hsa-miR-221-3p, hsa-miR-4745-5p, hsa-miR-107,
hsa-miR-363-3p, hsa-miR-4739, hsa-miR-514b-5p, hsa-miR-3175,
hsa-miR-6805-5p, hsa-miR-6769b-5p. Of 24 miRNAs, 3 were
upregulated in melanoma microenvironment as compared to
melanoma cells, whereas 21 were downregulated. Among these
microRNA, miR-106a-5p was the most downregulated in microen-
vironment, while miR-4433b-5p was found to be the most upreg-
ulated. Of the 24 differentially expressed miRNAs in the tumor
microenvironment, DIANA-miR-path identified 9 miRNAs with
predicted gene targets. MiR-106a-5p as the most upregulated in
melanoma tissue was identified to be involved in MAPK,
TGF-beta signaling pathways regulation. Besides, miR-106a-5p
participates in actin cytoskeleton regulation, adherens junction
and focal adhesion that may correspond to increased motility of
melanoma cells.
MicroRNA profiling may serve as useful tool for preliminary
microRNA search with following their target genes identification
for investigation of epigenetic regulation mechanisms in cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.084
P108
Participation of the genes MVP/LRP and YB-1 in the determination of
the rate of sensitivity of glioblastoma cells to temodal
E. Rybalkinaa,*, G. Pavlovab, N. Moiseevaa, O. Susovaa,
A. Mitrofanova, D. Panteleevb, N. Pustogarovb. aN.N. Blokhin
Cancer Research Center, Moscow, Russian Federation, b Institute of
Gene Biology of Russian Academy of Sciences, Moscow, Russian
Federation
⇑
Corresponding author.
Background: Glioblastomas (GBL) are most aggressive brain
tumors in adults. They are often radio- and chemotherapy resis-
tant. The standard therapy of GBL includes surgery followed by
radiotherapy with concomitant chemotherapy with temozolo-
mide named temodal (imidazotetrazine derivative). Methylation
of the O6-methylguanine-DNA-methyltransferase (MGMT) gene
promoter is considered as predictor of better outcome of temodal
therapy in comparison with the cases without MGMT promoter
methylation (Stupp et al., 2009). The aim of this study is finding
of additional predictors of temozolomide therapy effectiveness.
Materials and methods: We obtained primary cultures of GBL.
The rate of GBL sensitivity to temozolomide was revealed by
MTT test. Expression of multidrug resistance genes and genes
which mediate temozolomide sensitivity (YB1, MDR1, MRP1,
LRP, BCRP and MGMT) was determined by real time PCR. Protein
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